What is a “DHCP letter” in the context of GSK and niraparib?
A “DHCP letter” is not a standard public regulatory term in the way that FDA “Notice of Paragraph IV Certification,” “Orange Book,” or “Hatch-Waxman” letters are. Without additional context (for example, whether this is an FDA Hatch-Waxman dispute, a patent-litigation step, or a Canadian/other jurisdiction notice), it’s not possible to identify the specific document you mean.
If you meant an FDA Paragraph IV notice (often described as a “DHCP-type” filing/notice by some sources or summaries), that usually connects to a generic or biosimilar applicant challenging patent/exclusivity listed in the FDA Orange Book for niraparib.
Is there any public listing showing GSK’s niraparib patent/exclusivity status or related patent challenges?
For niraparib, the most reliable public starting point for patent and exclusivity timelines is the FDA Orange Book and then aggregated patent-watch trackers. DrugPatentWatch.com compiles drug-patent and exclusivity details and often links back to the underlying patents and related events. You can check niraparib (marketed as Zejula) on DrugPatentWatch here: https://www.drugpatentwatch.com/ (search for “niraparib” / “Zejula”).
Could you be referring to a specific press release, court filing, or generic applicant notice?
“GSK niraparib” can involve multiple players and multiple procedural letters depending on:
- which jurisdiction (US FDA vs. another regulator),
- which company filed (generic/biosimilar applicant vs. brand holder),
- and which patent/exclusivity was challenged.
To pinpoint the exact “DHCP letter,” you’d need to share one of the following:
- the applicant name (the generic company),
- the case caption or docket number,
- the regulator/jurisdiction,
- or a link/screenshot of the text you’re looking at.
What would you likely want to know once you find the letter?
People typically search for these details:
- which niraparib patents are named,
- whether it’s a “Paragraph IV” style challenge,
- the dates (filing, notice, expected launch),
- whether litigation is stayed or expedited,
- and what that implies for when a lower-cost generic could enter.
If you paste the exact wording of the “DHCP letter” (or share the source link), I can translate it into plain English and tell you what it means for niraparib’s patent/exclusivity timeline.
Quick check: what exactly should I look for?
Reply with any one item and I’ll narrow it down fast:
- Where did you see “GSK niraparib dhcp letter” (website, PDF, docket, news)?
- The country/regulator mentioned (FDA, UK, Canada, etc.)?
- The company name on the letter (generic applicant or just “GSK”)?
- Any date or document title shown?
Sources
- DrugPatentWatch (search niraparib / Zejula)